New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2013
09:19 EDTCUK, LCC, ING, CCL, CPWR, ARIA, ALUOn The Fly: Pre-market Movers
HIGHER: Alcatel-Lucent (ALU), up 9.4% following upgraded to Buy at Deutsche Bank... ING Group (ING), up 3.6% after upgrade at BNP Paribas... ARIAD (ARIA), up 6.5% after updating on R&D and commercial progress for a newly launched drug and one under development... Navidea Biopharmaceuticals (NAVB), up 7.8% after its Lymphoseek meets primary efficacy endpoint in trial... LOWER: Compuware (CPWR), down 2.1%, after warning its fourth quarter earnings and revenue are likely to sharply miss consensus estimates... US Airways (LCC), down 1.8% following downgrade to Neutral from Buy at Bank of America Merrill Lynch... Carnival (CCL), down 1.7% after its "Triumph" cruiseship reported to have broken loose from its dock in Alabama.
News For CPWR;LCC;ALU;CCL;CUK;ARIA;ING From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
10:02 EDTALUHigh option volume stocks
Subscribe for More Information
09:29 EDTINGING Group sees EUR 285M profit from divestments of Voya shares
Subscribe for More Information
March 2, 2015
06:32 EDTINGLarge EU banks may come under scrutiny for reciprocity, WSJ says
The banking practice of reciprocity -- giving work to competitor banks in order to foster relationships or reward past deals -- may come under investigation by the U.K. Financial Conduct Authority, reports the Wall Street Journal, citing a person familiar with the regulator. The FCA believes the practice may be anticompetitive, but it hasn't yet determined the scope of its investigation into EU banks. Publicly traded companies in the space include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), RBS (RBS) and UBS (UBS). Reference Link
05:42 EDTALUQualcomm, Alcatel-Lucent, T-Mobile enable extension of LTE
Subscribe for More Information
February 26, 2015
10:56 EDTARIAOptions with increasing implied volatility
Subscribe for More Information
February 24, 2015
13:07 EDTINGEU official: Euro banks shouldn't also go through Fed's stress test, WSJ says
Jonathan Hill, the European Unionís new financial markets chief, told The Wall Street Journal that he does not see a need for the U.S. to give stress tests to European banks that have already received health checks in Europe. Hill says banks across Europe are "properly and sensibly capitalized." The WSJ reported last week that the U.S. units of two European banks, Deutsche Bank (DB) and Banco Santander (SAN), are set to fail the Federal Reserve's stress tests, though they passed ECB stress tests last year. Reference Link
10:12 EDTARIAOptions with increasing implied volatility: LO ARIA OWW
February 23, 2015
10:45 EDTARIAOptions with increasing implied volatility
Subscribe for More Information
05:46 EDTARIAStocks with implied volatility movement; ARIA CYBR
Subscribe for More Information
February 20, 2015
06:35 EDTARIASarissa Capital seeks retirement of ARIAD CEO, board seats
Sarissa Capital disclosed in a regulatory filing that it has been in negotiations with members of ARIAD's board in an attempt to avoid a potential proxy contest. Sarissa said it indicated its belief that the board undertake measures to effect and facilitate the imminent retirement of Harvey Berger as CEO and that any settlement of a potential proxy contest must include the CEOís retirement. It added that no settlement has been reached. Sarissa believes the board "as currently constructed is not up to the task of providing the stewardship necessary to optimally navigate" the company. On February 19, Sarissa notified ARIAD that it intends to appear at the company's 2015 annual meeting of stockholders to nominate and seek to elect Richard Mulligan, Ph.D. and Anna Protopapas to the eight member staggered board of directors. Sarissa intends to seek to unseat Harvey Berger, ARIAD's Chairman and CEO, and Wayne Wilson, the lead independent director, with its two nominees. Sarissa added that it is "extremely concerned" with the conduct of certain members of the board, "particularly with respect to compensation, governance and financial matters." The hedge fund said it may ultimately initiate court proceedings to seek to remove one or more directors for cause based on potential breaches of their fiduciary duties. Sarissa Capital has a 6.9% stake in ARIAD.
February 19, 2015
14:21 EDTINGS&P reportedly says Greece contagion not a major risk, Reuters reports
The risk of contagion spreading from Greece to other European countries is not that large, a German newspaper quoted S&P's chief sovereign ratings officer as saying, according to Reuters. The euro zone would be able to handle an exit of the bloc by Greece, the ratings officer was quoted as saying, Reuters reported. Publicly traded European banks include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), RBS (RBS) and UBS (UBS). Reference Link
07:39 EDTARIAARIAD expects to file IND application for AP32788 this year
ARIAD says "We expect to file an investigational new drug application for AP32788 this year and to begin a Phase 1/2 proof-of-concept trial in 2016. This will be our third IND filing of an internally discovered oncology development candidate in the past eight years." The company also says "We anticipate presenting updates from the ongoing Phase 1/2 clinical trial of brigatinib at the 2015 European Lung Cancer Conference and the American Society of Clinical Oncology meetings later this year. Additionally, we expect to present preliminary data from the brigatinib ALTA trial in the second half of 2015."
07:38 EDTARIAARIAD sees FY15 net product revenues from sales of Iclusig $130M-$140M
Net product revenues from sales of Iclusig are expected to be in the range of $130M-$140M. This guidance includes sales of Iclusig in the U.S., Europe, and other select countries where ARIAD has distributorships in place. R&D expenses are expected to be in the range of $185M-$195M, reflecting increased development activities for Iclusig, brigatinib, and AP32788, as well as ongoing discovery research efforts. Expenses related to Iclusig represent approximately 50% of total R&D expenses and include the three new planned trials to begin this year, as well as all ongoing trials. Expenses related to brigatinib represent approximately 35% of total R&D expenses and include the two ongoing trials and NDA-enabling pre-clinical studies.
07:37 EDTARIAARIAD reports Q4 EPS (3c), consensus (20c)
Subscribe for More Information
06:04 EDTINGFCA to investigate investment and corporate banking
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use